Suppr超能文献

描述一些 SPG11 突变患者的 ARHSP/JALS 表型合并现象。

Description of combined ARHSP/JALS phenotype in some patients with SPG11 mutations.

机构信息

School of Biology, College of Science, University of Tehran, Tehran, Iran.

Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Mol Genet Genomic Med. 2020 Jul;8(7):e1240. doi: 10.1002/mgg3.1240. Epub 2020 May 8.

Abstract

BACKGROUND

SPG11 mutations can cause autosomal recessive hereditary spastic paraplegia (ARHSP) and juvenile amyotrophic lateral sclerosis (JALS). Because these diseases share some clinical presentations and both can be caused by SPG11 mutations, it was considered that definitive diagnosis may not be straight forward.

METHODS

The DNAs of referred ARHSP and JALS patients were exome sequenced. Clinical data of patients with SPG11 mutations were gathered by interviews and neurological examinations including electrodiagnosis (EDX) and magnetic resonance imaging (MRI).

RESULTS

Eight probands with SPG11 mutations were identified. Two mutations are novel. Among seven Iranian probands, six carried the p.Glu1026Argfs*4-causing mutation. All eight patients had features known to be present in both ARHSP and JALS. Additionally and surprisingly, presence of both thin corpus callosum (TCC) on MRI and motor neuronopathy were also observed in seven patients. These presentations are, respectively, key suggestive features of ARHSP and JALS.

CONCLUSION

We suggest that rather than ARHSP or JALS, combined ARHSP/JALS is the appropriate description of seven patients studied. Criteria for ARHSP, JALS, and combined ARHSP/JALS designations among patients with SPG11 mutations are suggested. The importance of performing both EDX and MRI is emphasized. Initial screening for p.Glu1026Argfs*4 may facilitate SPG11 screenings in Iranian patients.

摘要

背景

SPG11 突变可导致常染色体隐性遗传性痉挛性截瘫(ARHSP)和青少年肌萎缩侧索硬化症(JALS)。由于这些疾病具有一些共同的临床表现,并且都可能由 SPG11 突变引起,因此认为明确的诊断可能并不直接。

方法

对送检的 ARHSP 和 JALS 患者的 DNA 进行外显子组测序。通过访谈和神经学检查(包括电诊断学(EDX)和磁共振成像(MRI))收集具有 SPG11 突变的患者的临床数据。

结果

鉴定出 8 名 SPG11 突变的先证者。其中两种突变为新发现。在 7 名伊朗先证者中,有 6 名携带导致 p.Glu1026Argfs*4 的突变。所有 8 名患者均具有 ARHSP 和 JALS 均具有的特征。此外,令人惊讶的是,在 7 名患者中也观察到了 MRI 上存在薄胼胝体(TCC)和运动神经元病。这些表现分别是 ARHSP 和 JALS 的关键提示特征。

结论

我们建议,对于研究的 7 名患者,使用“ARHSP/JALS 综合型”来描述更为合适,而非 ARHSP 或 JALS。我们还提出了用于 SPG11 突变患者的 ARHSP、JALS 和 ARHSP/JALS 综合型的诊断标准。我们强调了进行 EDX 和 MRI 的重要性。对 p.Glu1026Argfs*4 进行初始筛查,可能有助于在伊朗患者中进行 SPG11 筛查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d64/7336765/3e6b153c4ca9/MGG3-8-e1240-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验